EBS Emergent BioSolutions Inc.

EMERGENT 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Emergent BioSolutions, Inc. – EBS

NEW ORLEANS--(BUSINESS WIRE)--

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until September 19, 2016 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions, Inc. (NYSE: EBS). Investor losses must relate to purchases of the Company’s common stock between January 11, 2016 and June 21, 2016. This action is pending in the United States District Court for the District of Maryland.

What You May Do

If you purchased shares of Emergent and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by September 19, 2016.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
17/09/2016

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Secures over $60 Million in New Contract Award w...

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox prep...

March 25, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to ...

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. “We’re pleased to welcome John to the board of directors at this important point in the company’s ongoing turnaround and transformation...

March 3, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financ...

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Ad...

February 26, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces New $50 Million Stock Repurchase Progr...

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company’s common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares. “In 2025, we were able to return value t...

February 26, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces Approximately $140 Million in Contract...

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada’s biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch